Laferobion

Laferobion is a drug that has antitumor, immunomodulatory, and antiviral properties. Does not have toxic effects.

[1]

Indications of the laferobion

The medicine is used for the combined treatment of such pathologies:

• in newborns (this includes premature babies) - with ARVI, meningitis with sepsis, pneumonia and various infections of the intrauterine type (such as chlamydia with mycoplasmosis and ureaplasmosis, herpes, systemic candidiasis and CMVI);
• in pregnant women - with lesions of the urogenital tract (such as ureaplasmosis with chlamydia and mycoplasmosis, papillomavirus, CMV, trichomoniasis, thrush and gardnerella with genital herpes), pyelonephritis with bronchogenic pneumonia, pulmonary diseases in the chronic stage, SARS, as well as with hepatitis B or C;
• with hepatitis category C, B or D in a chronic degree (children or adults), and in addition with hepatic cirrhosis, together with plasmapheresis and hemosorption procedures);
• with hepatitis types C, B or D in a chronic degree in children with oncology (leukemia or lymphogranulomatosis, as well as large neoplasms);
• in the acute stage of hepatitis type C in a child;
• with perinatal forms of hepatitis C, B or CMV in infants up to the age of 1;
• at acute stages of hepatitis types C or B for adults;
• adults with ARVI or influenza (this includes diseases that cause superinfection);
• with herpes on mucous membranes or skin;
• with papillomaviruses (anogenital or ordinary warts, as well as keratoacanthomas).

At the same time, Laferobion showed good results in treatment:

• ARVI along with influenza, insulin-dependent diabetes mellitus, and asthma in childhood;
• infectious lesions of bacterial or viral type - adults or children who are ill often and continuously;
• herpes with chlamydia, CMVI, ureaplasmosis and toxoplasmosis - adults or children;
• dysbacteriosis and pyelonephritis with glomerulonephritis, duodenitis or gastritis in the chronic stage, caused by enteroviruses of meningitis (serous type), mumps and diphtheria, localized to children;
• juvenile type of rheumatoid arthritis;
• meningeal tick-borne encephalitis;
• having a different origin of prostatitis;
• developed after surgery complications of a purulent type.

[2], [3]

Release form

The release is carried out in the form of suppositories, lyophilizate, as well as nasal powder.

Inside the pack - 3,5 or 10 suppositories in a blister.

The lyophilizate is contained in flacons with a volume of 1,000,000, 5,000,000 or 3,000,000 IU, 10 vials inside the pack. Also, the vial can have a volume of 6,000,000, 9,900,000 or 18,000,000 IU, 1 in the pack. Complete with the medicine may contain injectable liquid in ampoules (volume 1 or 5 ml) - the number of these ampoules corresponds to the number of bottles in the pack.

Nasal powder is available in 500000 IU dropper bottles, 1 bottle inside each pack. Or in bottles-droppers with a volume of 100,000 IU, 10 pieces inside the pack.

Pharmacodynamics

After the administration of drugs, the substance interferon reacts with specific conductors on the cell walls, thereby activating various intracellular reactions. Among these are protein production, inhibition of cell proliferation, stimulation of phagocyte activity with macrophages, and lymphocytes for target cells. Along with this, the drug depresses viral replication inside infected cells.

Pharmacokinetics

The peak level of drugs inside the body with the / m or s / c injection is noted after 3-12 hours after the procedure. The half-life is 3 hours.

Dosing and administration

Suppositories are required to be administered rectally.

The solution of the drug is administered in / m or iv way, and in addition, endolymph, intra-abdominal, rectal, intravesical, parabulbar or subconjunctival method. In addition, it is used in the form of drops for the nose and solution injected through the nebulizer. Injections are often administered using ampoules of 1,000,000 IU.

Newborns, as well as preterm infants, suppositories are administered in the amount of 150,000 IU. Children are required to enter the 1st suppository twice per day at intervals of 12 hours. This course lasts 5 days.

With the combined use of medication in newborns with pneumonia of bacterial origin, 150,000 IU are administered every day - 1 suppository three times a day for 7 days.

Infants of 4-6 months are administered 1 suppository with a volume of 500,000 IU twice a day, and children over half a year have 2 suppositories measuring 500,000 IU twice a day.

During combined therapy, children with hepatitis B, C, and D (chronic type) are prescribed 3,000,000 IU IFN / m2 ^of body area per day. The drug is prescribed daily in the amount of 1 suppository (2 injections per day) for 10 days and then following a similar scheme with application every other day for 0.5-1 year. The duration of the course is assigned with the account of laboratory and medicinal data.

When combined treatment of acute stages of hepatitis types B or C (adult), the drug is used in the amount of 3 million or 1,000,000 IU at the stage of long recovery or with a prolonged course of the disease. Also enter 2 times a day for 1 suppository with a multiplicity of days. Therapy lasts for 4-6 months.

During elimination in adult patients of hepatitis, which are of a viral nature (in a chronic stage), doses of 3,000,000 or 1,000,000 IU are administered daily - 1 suppository with a multiplicity of 2 times / day is administered for 1.5 weeks. Then, for half a year, apply after a day (if it is hepatitis type C) or during the first year in a day (if it is hepatitis type B).

In the process of complex therapy for influenza or acute respiratory viral infection (adults), suppositories in the amount of 500,000 IU are applied on the 1 st - twice a day for 5 days.

Complex therapy for severe stages of influenza or ARVI (children within the age of 1-7 years) suggests the use of suppositories 500,000 IU, and for children within 7-14 years - suppositories 1,000,000 IU. In such cases, the course lasts 5 days - 1 suppository 2 times / day.

For elimination of pyelonephritis, suppositories for 150,000 IU are needed - 1 unit is administered 2 times / day for 7 days, and then 2 suppositories per day (1 every 3 days) during the 1st month.

Nasal solution is most effective at the initial stage of the disease. To eliminate pathologies of viral-bacterial origin and ARVI, use nasal drops, inhalation, and also spray.

For instillation of 5 drops of the solution (a dose of 50000-100000 IU), which are injected into both nostrils at least 6 times a day at intervals of 1.5-2 hours. This therapy lasts no less than 2-3 days. Inhalation is also very effective.

The injection solution is released already in ready form or as a lyophilizate from which it can be made independently.

Dilute the powder in the ampoules with an injection liquid - enough 1 ml.

To treat the acute stage of hepatitis B, an injection of a solution of 1,000,000 IU is required (administered 2 times / day) for a period of 6 days, after which the dosage is reduced-the same dose is administered, but once a day, for a period of 5 days. It is forbidden to use drugs if the patient has hepatic coma or hepatitis of cholestatic origin.

If the above disease occurs in chronic form, it is required to administer 3-6 million IU once a day at a frequency of 24 hours. This course lasts a maximum of 24 weeks.

To get rid of tick-borne encephalitis, 1 to 3 million IU of medication is used 2 times / day for 10 days, after which maintenance therapy is performed - the same dosage, but injected once with an interval of 1 day for 10 days .

Treatment of oncological pathologies involves the use of the maximum possible portions. In Laferobion, only the cytostatic effect, because of what it is required to use after regression of the neoplasm or when the patient has a remission.

During the treatment of chronic myelogenous leukemia, 900,000 IU is prescribed every day until remission is achieved, after which maintenance portions are used: the same dose, but with application every other day.

To eliminate lymphocytic leukemia, 3,000,000 IU of medication is required daily until there is an improvement, and then go on to supportive therapy-to administer the same dose three times per week.

In the treatment of Kaposi's angiosarcoma, it is required to administer 36 million IU every day for a long period of time. To stabilize the condition, the patient is transferred to maintenance doses: 18 million IU three times a week.

[4]

Use of the laferobion during pregnancy

Pregnant or lactating mothers are prohibited from using Laferobion. If it is necessary to treat using drugs, it is necessary to be guided by the ratio of the benefits for the woman and the risk of complications in the fetus.

Contraindications

Among the contraindications:

• intolerance to α-interferon or other elements of the drug;
• hepatitis of autoimmune origin;
• hepatic pathology of decompensated nature;
• scores less than 50 ml / minute;
• a history of hemoglobinopathy.

Side effects of the laferobion

Use of the drug can cause the development of some side effects:

• development of influenza-like manifestations: myalgia, chills, fever, asthenia, severe dizziness, pain in the eyes, fatigue and headaches;
• systemic disorders: dehydration, allergic symptoms, hyperglycemia, sensation of weakness, hypercalcemia, lymphadenitis with lymphadenopathy, and in addition hypothermia, peripheral puffiness and superficial phlebitis;
• damage to the hematopoietic system: the development of anemia, thrombocyto-, neutro-, leuko- or granulocytopenia, and in addition to this lymphocytosis;
• reactions from the CCC: the emergence of angina pectoris, extrasystole, arrhythmia, bradycardia with tachycardia, and in addition ventricular fibrillation and a decrease in blood pressure;
• violations of the endocrine function: the development of hyper- or hypothyroidism, and in addition to this virilism or gynecomastia;
• disorders in the hepatobiliary system: the development of hepatitis or hyperbilirubinemia, as well as an increase in LDH and liver enzymes;
• disorders of the gastrointestinal tract: the development of gingivitis or anorexia, the emergence of abdominal pain, vomiting, dyspepsia, nausea and diarrhea;
• lesions in the field of ODA: the development of hyporeflexia, spondylitis and arthrosis with arthritis, and in addition tendonitis, nodular polyarteritis and muscular atrophy, as well as the appearance of seizures;
• disorders of urogenital function: the development of impotence, amenorrhea or dysmenorrhea, as well as problems with urination;
• mental disorders and problems from the NA: development of apathy, depression, migraine, tremor, aphasia, polyneuropathy and amnesia. Also there are paresthesia, sleep disorders, problems with coordination and gait, hyperesthesia, extrapyramidal symptoms, a feeling of excitement and dizziness;
• lesions of the respiratory system: the appearance of rhinitis, cough and dyspnea;
• problems with the skin: the appearance of itching, the development of dermatitis or alopecia.

Overdose

Due to intoxication with Laferobion, there may be disorders of consciousness, lethargy and a sense of prostration. These symptoms are reversible and pass after stopping the use of drugs.

Interactions with other drugs

Laferobion can be combined with any drug, which is often used during the treatment of the diseases described above (antibiotics, GCS, chemotherapy, immunosuppressors, and inducers of interferon substance).

[5], [6]

Storage conditions

Laferobion is required to be kept out of the reach of small children. Medication is usually stored in the refrigerator in order to comply with the limits for temperature: 2-8 ^of C.

Special instructions

Reviews

Laferobion in all forms of manufacture usually has either positive or neutral reviews. Well about him, and parents who used the drug to children during combined treatment for influenza, ARVI, and other pathologies respond.

Shelf life

Laferobion is allowed to be used for 3 years after the release of the medicine. A ready-made solution of powder is allowed to be stored for a maximum of 1 day.